“Wrong” analysis: US environmental agency needs to re-examine glyphosate risk

“Defective” analysis
The US Environmental Protection Agency needs to reassess the risk of glyphosate

Since the Monsanto acquisition, the Bayer Group has had a major legal yard in the United States, with the Roundup herbicide at the center. In one day, there are two important judicial decisions independently of each other. One affects Bayer directly, the other indirectly.

The US Environmental Protection Agency was ordered by an appeals court to review the health risks of glyphosate. The San Francisco court questioned the EPA’s assessment that the active ingredient in Bayer’s controversial Roundup herbicide poses no particular risk to humans.

The topic is of great importance to the German group Bayer. It is facing numerous US lawsuits in the United States for alleged cancer risks due to glyphosate. There was also good news for the DAX company on Friday: in one case in the state of Oregon, it got another success in court. Bayer has now won the last four US lawsuits involving plaintiffs blaming glyphosate for cancer.

Last exam two years ago

The EPA last looked at the herbicide in 2020 and said it posed no health risk when used correctly. The environmental organization NRDC, among other things, has complained about this. “For years, the EPA has refused to do anything about the harmful effects of this pesticide on humans and the environment,” the organization said Friday. The court made it clear that this could not be the case.

In its ruling, the competent appeals court was particularly bothered by the way the EPA justified that glyphosate is not carcinogenic. The background analysis is “wrong” and is not in line with the authority’s guidelines. The EPA declined to comment on the criticism when asked. A spokesperson said the glyphosate decision will be reviewed.

In a statement, Bayer expressed confidence that the EPA found no cancer risks from glyphosate even in a new review. The US government’s environmental agency last acted conscientiously and made a “rigorous” evaluation of scientific studies over the past 40 years. Bayer took on the glyphosate lawsuits with the $ 60 billion acquisition of seed giant Monsanto in 2018.

Bayer wants to appear “confident”.

The numerous procedures in the USA are based in particular on an evaluation by the International Agency for Research on Cancer of the World Health Organization. In 2015, it classified Monsanto’s herbicide as “possibly carcinogenic” to humans. Bayer denies this, arguing with approval from many regulatory agencies and studies that aim to prove that glyphosate is safe when used as directed.

The tide has finally turned after Bayer lost its top three glyphosate lawsuits in the United States. On Friday the DAX group won the fourth consecutive procedure. The Jackson County, Oregon Grand Jury found Roundup unanimously not responsible for plaintiff’s cancer. “We stand completely behind Roundup’s safety,” Bayer said. The group announced that it would “defend itself with confidence” in all future legal conflicts on the matter.

About the author


Leave a Comment